Excess endothelin has been found in people with pulmonary hypertension, causing constriction in the blood vessels in the lungs. Endothelin receptor antagonists are designed to block the excess endothelin by various means.
SSc-PAH Outcomes Worse With Initial ERA. Time to clinical worsening was significantly faster with an endothelin receptor antagonist (ERA) as primary therapy for systemic sclerosis-related pulmonary arterial hypertension compared with a phosphodiesterase-5 (PDE5) inhibitor, or the combination of a PDE5 inhibitor and an ERA, researchers reported. MedPageToday.
Bosentan (Tracleer) by Actelion is proving useful for a variety of scleroderma symptoms, including pulmonary fibrosis, pulmonary hypertension, Raynaud's, and skin fibrosis. ISN.
Letairis (Ambrisentan) by Gilead is an endothelin receptor antagonist for pulmonary hypertension. ISN.
Early treatment with ambrisentan of mildly elevated mean pulmonary arterial pressure (mPAP) associated with systemic sclerosis. This is the first randomized, double-blind, placebo-controlled study testing the effect of ambrisentan in patients with mildly elevated mPAP and/or exercise pulmonary hypertension. PubMed, Arthritis Res Ther, 2019 Oct 26;21(1):217. (Also see Letairis (Ambrisentan) and Clinical Trials)
Macitentan (Opsumit) by Actelion is an oral dual endothelin receptor antagonist for pulmonary hypertension, which submitted its FDA approval application in October 2012. ISN.
SCLERO.ORG is the world's leading nonprofit for trustworthy research, support, education and awareness for scleroderma and related illnesses. We are a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team. Donations may also be mailed to: